HAVING WORKED FOR MANY YEARS on relatively basic questions germane to the venerable renin-angiotensin system, we were musing with some fascination recently on the continuing evolution of our understanding of the system. In particular, we were taking note of the considerable amount of dogma, with varying levels of verification associated with the system, as well as the almost continuous infusion of remarkable new twists and turns that seem to mark the passing of time. We were also struck by the existence of a surprising number of unresolved core issues.
It was noted early on by Taugner and Hackenthal (24) that the secretory pathway in the renal juxtaglomerular cell of rats appeared to involve granules that had the characteristics of modified lysosomes. Not surprisingly, cathepsin B, along with a number of other lysosomal enzyme candidates, was shown to exhibit cellular and organelle colocalization with prorenin.
A series of straightforward studies undertaken by Hsueh and colleagues were particularly persuasive. They purified human active renin and undertook amino terminal sequencing (4) . The results indicated that prorenin appeared to be converted to renin through cleavage at the carboxyl end of a Lys-Arg dibasic amino acid doublet (residues 65-66 of preprorenin). Using a recombinant human prorenin as a substrate, they then went on to purify an enzymatic activity associated with a thiol protease from human kidney that accurately processed prorenin to renin in vitro, suggesting that a cysteine protease was the authentic renal PPE (23) . Subsequent studies revealed that cathepsin B, of both renal and liver origin, correctly corresponded with enzymatic activity and that cathepsin B hydrolyzed the 43 amino acid prosegment of prorenin without further degrading renin (25) . Importantly, cathepsin B exhibited colocalization with renin in juxtaglomerular cell secretory granules. Confirmation that cathepsin B was uniquely the juxtaglomerular PPE could have been demonstrated by showing that cathepsin B inhibitors prevented prorenin processing in vivo or in cultured juxtaglomerular cells. Whether the inhibition studies were performed is unclear.
Neves et al. (18) showed that cotransfection of cathepsin B and human preprorenin expression vectors into secretory granule-containing rat GH4C1 cells resulted in enhanced generation of secretable active renin relative to the preprorenin vector alone. This suggests that cathepsin B could localize to the appropriate cellular compartment to effect correct processing in an intact cell. The ratios of active renin to prorenin secreted, however, were not particularly high, and they thus carefully pointed out that, while these results were consistent with such a role for cathepsin B, they did not constitute proof that cathepsin B was the bona fide PPE.
Jutras and Reudelhuber (9) used scanning mutagenesis to identify the amino acids determining site selectivity of human prorenin cleavage by human cathepsin B in vitro. Their results suggested that the basic residue, lysine, at Ϫ2 (relative to the cleavage site) was required for cleavage in vitro, consistent with predictions of cathepsin B mechanism from activity on synthetic substrates.
All of the above data are consistent with cathepsin B comprising the PPE, but a number of less satisfying observations have also been reported. In particular, amino terminal sequencing of active renins from other species revealed that the NH 2 terminus of active renin does not appear to be necessarily conserved. Active renin 2 enzyme, a curious nonglycosylated renin derived from an evolutionarily recent gene duplication event unique to mice, as isolated from mouse submandibular gland, exhibits an NH 2 terminus homologous to human renal renin (15) . In contrast, the sequence of active mouse renin 1, as isolated from the As4.1 cell line (8), a putative model for mouse renal juxtaglomerular cells derived by transgene-targeted tumorigenesis, exhibits an NH 2 terminus that lies seven amino acids downstream from the site reported for human kidney renin. Interestingly, this site is homologous to that observed for rat renal renin by Kim et al (11) .
The primary amino acid sequences for rat, human, and mouse renin 1 and 2 are shown in Fig. 1 with the presumptive cleavage sites specified. It is interesting to note that the dibasic amino acid doublet corresponding to residues 65-66 of human preprorenin (42-43 of prorenin) is evolutionarily conserved, although there is substitution of Lys-Lys in the case of the rat for the Lys-Arg found in mouse and human, and there are potentially significant amino acid substitutions evident in the immediate vicinity of the doublet. In particular, mouse renin 1 exhibits a proline for leucine substitution, while the rat sequence bears more similarity to the mouse renin 2 sequence with a serine doublet in place of the leucine threonine of human. As pointed out in the DISCUSSION by Mercure et al, (13a), one explanation might be that the initial cleavage in all three species is performed by cathepsin B but that the mouse and rat renins are subsequently trimmed by other enzymes to generate the observed termini. Alternatively, different processing enzymes might be involved in activating human renin vs. rat and mouse renins. A lack of evolutionary conservation for the processing of an enzyme that plays such a central role in physiology as renin is unsettling, or at least intellectually unappealing, however; and the conservation of the dibasic doublet, despite the adjacent sequence variation could be taken to argue against this radical notion.
Consistent with the possibility that an initial cleavage at the dibasic site is followed by "nibbling" is a report by Almeida et al. (1) who used an internally quenched fluorescent peptide assay to demonstrate that the species-specific cathepsin B's could appropriately cleave peptides mimicking the respective species-specific dibasic doublet processing sites for rat and human. At present, it is unclear how the less homologous substitution of proline, in the case of mouse renin 1, would affect cleavage at this site although there are statements in previous papers (12) suggesting three enzymes that have been found to be capable of activating human renin, cathepsin B, and the convertases PC1 and PC5, are incapable of activating mouse renin 1 and rat renin in the cell transfection assays employed. As a point of information, the convertases PC1 (2) and PC5 (14) have been shown to be capable of activating human renin and mouse renin 2, but it appears unclear that PC1 and PC5 exhibit appropriate cell specificity to fulfill the role of the renal PPE in humans. They have been proposed to potentially perform this role at other sites, e.g., adrenal, in humans. Again, however, there appears to be a disturbing lack of evolutionary conservation.
In vivo release of renin from juxtaglomerular cells is thought to be mediated via two pathways (20) . Processed active renin is secreted from dense modified lysosomal storage granules in response to physiological cues, while the inactive zymogen is constitutively released via clear vesicle fusion with the plasma membrane. Support that the secretory granules are, in fact, secretory lysosomes has been provided by studying the influence on granule morphology by genetic mutations such as the Beige mutation, which causes a lysosome secretory defect (7). In contrast, many of the cellular assays that have been described above have been performed in cultured cell lines that are characterized as having regulated secretory pathways characteristic of other tissue sites, e.g., rat pituitary GH4C1 cells (18) and mouse pituitary AtT20 cells (13) . Renin release from juxtaglomerular cells is a highly regulated process (21) . Renin release is stimulated by activation of the cAMP pathway and inhibited by elevation of intracellular Ca levels. It is unclear whether the cellular models that have been employed to study prorenin processing are genuinely representative of the processing/secretory pathway of juxtaglomerular cells. As pointed out by Jutras and Reudelhuber (9) in their cellular cotransfection studies of cathepsin B and human prorenin in AtT20 cells, it appears that cathepsin B is correctly sorted to lysosomes through modified mannose residues and does not appear to be cosecreted with renin from the regulated pathway. These observations raise the question of how cathepsin B could be mediating the processing if the two proteins are not coresident within the cells. It has been proposed that in the overexpression systems employed there may be sufficient activation of cathepsin B in early stages of the secretory process, where the proteins are coresident in the trans-Golgi and immature granules to achieve processing of prorenin before they segregate to their respective compartments.
In contrast, there is a large body of evidence suggesting colocalization of renin and lysosomal enzymes in renal juxtaglomerular cells (24) . Renin gene ablation studies in vivo have provided some interesting insights, suggesting that the trafficking and maturation processes studied in the in vitro cell culture systems may not be mirroring the intact kidney. The Mullins laboratory (22) differentially knocked out the Ren1d and Ren2d loci in a strain that harbors both loci. Ren1d gives rise to the glycosylated renin 1, whereas Ren2d gives rise to the atypical nonglycosylated renin 2. The Ren2 knockout resulted in no observable histomorphological alterations to juxtaglomerular cell morphology as monitored by electron microscopy (22) , while ablating expression of Ren1d led to a change in immunostaining from a punctuate, abundant granular pattern to diffuse, weak cytoplasmic staining. Electron microscopy re- Fig. 1 . Primary amino acid sequences for rat, human, and mouse renin 1 and 2 , with the presumptive cleavage sites specified.
vealed a complete absence of dense granule formation in the Ren1d-deficient mice (3). The results suggest that the signals required for sorting to the regulated pathway of juxtaglomerular cells in vivo are restricted to the renin 1 protein and further suggest that renin 1 and renin 2 are secreted by distinct pathways in vivo. Parallel studies by Gomez's laboratory in Ren1d-Ren2d mice (19) and Fukamizu's laboratory in strains of mice harboring only the single Ren1c locus (26) exhibited a similar phenotype. In an elegant set of studies, Mullins et al. (16) went on to demonstrate that a bacterial artificial chromosome (BAC) harboring wild-type Ren1d and Ren2d could completely rescue granulation and other aspects of the phenotype in otherwise renin-deficient mice. On the contrary, a BAC harboring a Ren1d locus into which a Lac reporter cassette had been inserted, disrupting Ren transcription, was incapable of rescuing the granulation phenotype. Importantly, reporter expression clearly indicated expression in bona fide juxtaglomerular cells. These studies also demonstrated that overexpression of renin 2 could not compensate for the loss of renin 1 and indicate that an active Ren1 locus is essential and sufficient for normal morphology of the juxtaglomerular apparatus. They note that the salient difference between renin 1 and renin 2 lies in the three N-linked glycosylation sites that characterize the renin 1d and renin 1c sequences in contrast to the renin 2 sequence, and that human and rat renin also exhibit two of the three potential glycosylation sites. It is hypothesized that these may be the signal for trafficking and generation of dense granules, presumably via a modified lysosome pathway (5) .
The present study by Mercure et al. (13a) demonstrates by the most rigorous state-of-the-art means that cathepsin B is not supported to be the relevant PPE in vivo for generation of renin in the mouse. In view of the disparities observed between human and mouse renin 2 vs. rat and mouse renin 1 for in vitro processing by cathepsin B, it might be of interest to assess the effect of the cathepsin B knockout on a Ren1d knockout line where Ren2 is the only contributing locus, or a complete mouse Ren knockout harboring a human Ren transgene (or humanized renin-angiotensin system). In the end, it is ironic that it has taken so long to perform this critical test; in some respects it would appear to confirm that a negative result needs to be performed in a sexier context in order to see the light of day in the literature. We can thank the Reudlhuber lab for definitively reopening the search for the elusive PPE by reinforcing what is known and not known and opening our thoughts to other explanations and possibilities.
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